IMF TV

From our weekly series “Ask Dr. Durie” to comprehensive news from key cancer medical conferences around the world, IMF-TV is your all-access ticket to critical myeloma research, patient education and guidance. Check back often for regularly updated content. 

Jan
11
Best of ASH 2017
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma(...)
Jan
10
Should the cost of Revlimid (lenalidomide) be reduced?
In this week’s video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.
Jan
05
Should myeloma patients be tested further if they have excellent responses to initial treatment?
In this week’s video, Dr. Brian G.M. Durie explains which tests should be used to monitor the possible progression of myeloma. The BOTTOM LINE: Even if your myeloma protein is at a low level, set up(...)
Dec
22
Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Vs VMP in NDMM Pts Ineligible for Transplant (ALCYONE)
VMP is a standard of care (SOC) for transplant ineligible NDMM. Daratumumab (D), a human IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and multifaceted immunomodulatory mechanism of(...)
Dec
22
Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR)
Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder that includes patients with different risk of progression to Multiple Myeloma (MM). The Spanish Myeloma Group demonstrated(...)
Dec
19
Daratumumab in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001)
Standard of care treatments for patients (pts) with newly diagnosed multiple myeloma (NDMM) include triplet regimens containing a proteasome inhibitor (PI) or an immunomodulatory drug (IMiD), with or(...)